Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin‐Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti‐PCSK9 Antibody in Statin‐Intolerant Subjects 3 (GAUSS‐3) Trial

Statins are the accepted standard for lowering low‐density lipoprotein cholesterol (LDL‐C). However, 5% to 10% of statin‐treated patients report intolerance, mostly due to muscle‐related adverse effects. Challenges exist to objective identification of statin‐intolerant patients. Evolocumab is a mono...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Cardiol
Main Authors: Nissen, Steven E., Dent‐Acosta, Ricardo E., Rosenson, Robert S., Stroes, Erik, Sattar, Naveed, Preiss, David, Mancini, G.B. John, Ballantyne, Christie M., Catapano, Alberico, Gouni‐Berthold, Ioanna, Stein, Evan A., Xue, Allen, Wasserman, Scott M., Scott, Rob, Thompson, Paul D.
Format: Artigo
Sprog:Inglês
Udgivet: Wiley Periodicals, Inc. 2016
Fag:
Trial Designs
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6490723/
https://ncbi.nlm.nih.gov/pubmed/26946077
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.22518
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker